"Biomateriali's high quality vascular grafts fit well in our product range and will leverage our growing European sales force," said George W. LeMaitre, Chairman and CEO of LeMaitre Vascular. "We recently announced plans to sell our products directly to Italian hospitals starting in January, 2008. The Biomateriali acquisition should complement this direct-in-Italy initiative."
The Company does not expect to record Biomateriali revenue for the balance of 2007. It is expected that this acquisition will be dilutive in 2008. The Biomateriali acquisition does not change the Company's previous 2007 revenue guidance of $40.5 million to $41.3 million. The Company will issue its financial guidance for 2008 at its next earning call.
LeMaitre Vascular will be hosting a conference call to discuss the Biomateriali acquisition at 8:30am EST, Friday, December 21, 2007. The dial-in number is (866) 314-5232 (+1-617-213-8052 for international callers), using passcode 80933846. A replay of the call will be available for 30 days thereafter at http://www.lemaitre.com/investor.
This press release contains forward-looking statements within the
meaning of the U.S. Private Securities Litigation Reform Act of 1995.
Statements in this press release regarding the Company's business that are
not historical facts may be "forward-looking statements" that involve risks
and uncertainties. Specifically, statements regarding the Company's
financial guidance and its operational objectives, the polyester graft
market opportunity, and the Company's ability to integrate the acquired
operations and products into its business, are forward-looking statements
involving risks and uncertainties. Forward-looking statements are based on
management's current, preliminary expectations and
|SOURCE LeMaitre Vascular, Inc.|
Copyright©2007 PR Newswire.
All rights reserved